Journal of Personalized Medicine最新文献

{"title":"Personalized Profiles of Autonomic Regulation in Elite Athletes: Analysis of Genetic and Cardiorespiratory Determinants Using Decision Tree Modeling.","authors":"Irina Bacheva, Lyazat Ibrayeva, Dina Rybalkina, Irina Kadyrova, Diana Zhumagaliyeva","doi":"10.3390/jpm16040230","DOIUrl":"https://doi.org/10.3390/jpm16040230","url":null,"abstract":"<p><p><b>Backgrounds</b>: The aim of this pilot study was to evaluate the hierarchical contribution of individual genetic polymorphisms to the variability of autonomic regulation parameters and respiratory function in athletes of different sport specializations using Classification and Regression Tree (CRT) analysis. <b>Methods</b>: The study included athletes divided into two groups: hockey players (<i>n</i> = 48) and martial artists (<i>n</i> = 43). Heart rate variability (LF, HF) parameters and spirometric indices (FEV₁) were assessed. Genetic analysis included 8 single nucleotide polymorphisms (SNPs): IL6 rs1800795, VDR rs731236, KCNJ11 rs5219, ADRB2 rs1042713, ADRB2 rs1042714, TRHR rs16892496, MSTN rs1805086, UCP3 rs1800849. <b>Results</b>: In martial artists, the main predictors were genes responsible for adrenoreceptor sensitivity (ADRB2) and neuroimmune interactions (IL6). In hockey players, the most significant predictors were genes involved in muscle growth (MSTN), energy metabolism (UCP3), and neuroendocrine regulation (TRHR). These findings indicate that similar resting HRV parameters in athletes from different sports may be associated with different genetic polymorphisms, reflecting sport-specific physiological adaptations to training loads. <b>Conclusions</b>: The results highlight the sport-specific nature of genetic determinants of autonomic regulation. In martial artists, genes related to the immuno-adrenergic axis (IL6, ADRB2) appear to play a dominant role, whereas in hockey players neuroendocrine, muscle-metabolic, and mitochondrial factors (TRHR, MSTN, UCP3) demonstrate greater influence. The observed interactions between genotypes and FEV₁ emphasize the importance of transitioning from generalized approaches toward personalized monitoring strategies in sports science.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"16 4","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13117278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of Concern: Dellino et al. Effects of Oral Supplementation with Myo-Inositol and D-Chiro-Inositol on Ovarian Functions in Female Long-Term Survivors of Lymphoma: Results from a Prospective Case-Control Analysis. <i>J. Pers. Med.</i> 2022, <i>12</i>, 1536.","authors":"Journal Of Personalized Medicine Editorial Office","doi":"10.3390/jpm16040227","DOIUrl":"https://doi.org/10.3390/jpm16040227","url":null,"abstract":"<p><p>With this notice, the <i>Journal of Personalized Medicine</i> Editorial Office and Editorial Board wishes to alert readers to concerns related to this article [...].</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"16 4","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13117468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized Diabetes Therapy Part 2-Individual Diabetes Treatment (Standard of Care Plus, SOC+).","authors":"Julia Jantz, Andreas Pfützner","doi":"10.3390/jpm16040229","DOIUrl":"https://doi.org/10.3390/jpm16040229","url":null,"abstract":"<p><p>Conventional diabetes therapy primarily targets HbA1c using a standardized, stepwise approach, often neglecting individual clinical and diagnostic phenotypes. In this second part of our discussion, we present an alternative strategy. After phenotyping the patient, we initiate a targeted pharmacological combination therapy tailored to the individual's underlying pathophysiology, alongside lifestyle modifications. Sulfonylureas are completely avoided in this approach. Instead, medications are selected based on their alignment with the patient's phenotype and absence of contraindications. Early insulin therapy, for example, is particularly effective in patients with β-cell-dysfunction-driven diabetes, whereas GLP-1-supported weight reduction and glitazone therapy are more suitable for insulin-resistance-driven diabetes. For monitoring and determining when temporary therapy intensification may be necessary, we rely on a combination of functional biomarkers (intact proinsulin, adiponectin, hsCRP, and leptin) and conventional clinical parameters (HbA1c, BMI, lipids, blood pressure). Using this personalized strategy, we have consistently achieved long-term glycemic control-often maintaining normal HbA1c levels for up to 15 years in our patients so far.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"16 4","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13117158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine Perfusion Across Marginal Liver Grafts: Benefits and Challenges.","authors":"Leandro Sierra, Maria Ortega Abad, Maria Saavedra-Martinez, Kanisha Bahierathan, Zainab Ifthikar, Ana Eliza Velez, Nikki Duong, Luis Antonio Diaz, Juan Pablo Arab","doi":"10.3390/jpm16040228","DOIUrl":"https://doi.org/10.3390/jpm16040228","url":null,"abstract":"<p><p>Liver transplantation is the definitive therapy for end-stage liver disease, yet persistent organ shortages result in approximately 10% of recovered livers being discarded, with markedly higher discard rates among marginal grafts from elderly donors, donation after circulatory death (DCD), and those with macrovesicular steatosis. Machine perfusion (MP) has emerged as a paradigm-shifting preservation strategy with the potential to safely expand the usable donor pool. This narrative review examines the current evidence for three MP modalities-hypothermic machine perfusion (HMP), normothermic machine perfusion (NMP), and normothermic regional perfusion (NRP)-across various marginal donor populations, including elderly donors, steatotic grafts, donors with infectious diseases, and split liver transplantation. Current evidence demonstrates that MP significantly increases utilization of steatotic grafts with up to an eightfold rise in usage of severely steatotic organs. HMP consistently reduces non-anastomotic biliary strictures and early allograft dysfunction across donor types, while NMP enables real-time viability assessment and reduces post-reperfusion syndrome in steatotic grafts. NRP shows particular benefit in DCD organs, reducing biliary complications and improving one-year survival. Additionally, MP extends preservation times enabling next-day split liver transplantation and shows promise as a platform for ex situ antiviral therapy. Despite compelling evidence supporting MP in marginal grafts, widespread adoption remains constrained by high costs, logistical complexity, and the absence of standardized protocols. Future progress will require multicenter studies evaluating long-term outcomes alongside consensus-driven implementation frameworks.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"16 4","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13117558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Body Mass Index Lacks Predictive Influence on Perioperative, Short-Term Follow-Up, and Patient-Reported Outcomes from Holmium Laser Enucleation of the Prostate.","authors":"Jack T Peterson, Jenny N Guo, Amir Patel, Nabila Khondakar, Perry Xu, Amy E Krambeck","doi":"10.3390/jpm16040225","DOIUrl":"https://doi.org/10.3390/jpm16040225","url":null,"abstract":"<p><p><b>Background/Objectives</b>: Obesity has been associated with the development and severity of benign prostatic hyperplasia (BPH), yet its influence on outcomes following definitive surgical management, like holmium laser enucleation of the prostate (HoLEP), remains unclear. Furthermore, gradation of body mass index (BMI) severity has yet to discern personalized outcome stratification. We evaluated BMI's influence on perioperative, immediate, short-term follow-up, and patient-reported outcomes for HoLEP patients. <b>Methods</b>: We performed a retrospective review of a prospectively maintained database of patients undergoing HoLEP for BPH at a single institution between January 2021 and August 2025. Outcomes included operative characteristics, post-operative complications, and validated symptom score changes. Analyses treated BMI as both a continuous and categorical variable. Multivariable linear and logistic regression models adjusted for common colinear confounders. <b>Results</b>: Among 1445 patients, BMI was not associated with most immediate, three-month, or patient-reported outcomes. Surgical complications were low across all BMI categories, and post-operative reported outcomes indicating high success rate for HoLEP. Higher BMI correlated with a modest increase in enucleation time (β = 0.197; <i>p</i> = 0.0132), increased odds of dysuria (OR = 1.084; <i>p</i> < 0.001), and change in American Urological Association Symptom Score (β = 0.211; <i>p</i> = 0.0334). All other operative metrics, complication rates, continence outcomes, and symptom scores (17 other total) were independent of BMI. <b>Conclusions</b>: After adjustment for relevant confounders, BMI does not meaningfully predict surgical safety, functional recovery, or patient-reported benefit following HoLEP. BMI alone should not influence candidacy or risk stratification for HoLEP in patients with BPH, instead favoring personalized, risk-stratified approaches.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"16 4","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13117023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized Diabetes Therapy Part 1-Functional Phenotyping as a Conceptual Basis for Individualized Treatment.","authors":"Andreas Pfützner, Julia Jantz","doi":"10.3390/jpm16040226","DOIUrl":"https://doi.org/10.3390/jpm16040226","url":null,"abstract":"<p><p>The diagnosis of type 2 diabetes using classical clinical and laboratory biomarkers (HbA1c, glucose, lipids, BMI, and blood pressure) is a classification by symptoms and does not provide insight into the underlying pathophysiological disorders (insulin resistance, β-cell dysfunction, visceral adipose tissue hormonal secretion, and chronic systemic inflammation). A better understanding of these disorders may help in the selection of appropriate and potentially more successful personalized therapeutic interventions. Based on extensive clinical trial experience, a method for individual phenotyping and consecutive personalized diabetes therapy has been developed in our practice, which we have been using for more than 15 years and would like to share for discussion and debate. In this Part 1, the pathophysiological background and diagnostic approach to phenotyping is described. A consecutive Part 2 will present the translation of the phenotyping result into a personalized diabetes therapy, and another consecutive Part 3 will provide more comprehensive real-world patient observations when practicing this concept. This article is intended as a discussion/concept paper and does not present unpublished patient-level outcome data or formal effectiveness analyses. Prospective validation studies are needed to evaluate the clinical utility of this phenotype-based framework.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"16 4","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13117687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) with Mepolizumab or Dupilumab: A Preliminary Single-Center Study for Evaluation of Safety and Efficacy.","authors":"Melania Bertolini, Lorenzo Fucci, Luca Guastini, Carlo Conti, Gregorio Santori, Frank Rikki Mauritz Canevari","doi":"10.3390/jpm16040224","DOIUrl":"https://doi.org/10.3390/jpm16040224","url":null,"abstract":"<p><p><b>Background:</b> The study aims to analyze the safety and efficacy of Mepolizumab and Dupilumab in the treatment of patients affected by severe chronic rhinosinusitis not controlled with nasal polyposis (CRSwNP) from a tertiary care regional referral center, with the aim of improving the concept of personalized medicine. <b>Methods:</b> A retrospective study was conducted on 72 adult patients selected for biologic therapy according to EPOS/EUFOREA criteria. The patients received either Mepolizumab or Dupilumab. Primary endpoints were reduction in nasal polyp size, improvement in disease-specific quality of life (sinonasal outcome test-22, visual analog scale), olfactory recovery, and asthma control. Secondary outcomes were the assessment of adverse events. <b>Results:</b> Both monoclonal antibodies significantly improved nasal polyps score (NPS), sinonasal outcome test-22 (SNOT-22), and asthma control test (ACT) over time, with no statistically significant differences between Mepolizumab and Dupilumab. In contrast, blood eosinophil counts showed significant differences: Dupilumab was associated with a transient increase in eosinophil levels (absolute Δ = 660.08% Δ = 9%; <i>p</i> < 0.001), while Mepolizumab produced a marked reduction (absolute Δ = 192.52% Δ = 2%; <i>p</i> < 0.001). Both treatments were well tolerated, with only mild adverse events reported. <b>Conclusions:</b> Mepolizumab and Dupilumab are both effective and safe in improving sinonasal symptoms and quality of life in severe uncontrolled CRSwNP. While improvements in NPS, SNOT-22, and ACT scores were comparable, Mepolizumab achieved a significant reduction in eosinophil counts, whereas Dupilumab was associated with faster clinical improvement but a transient eosinophilia. These findings suggest that biologic choice may be guided by individual patient profiles and inflammatory patterns.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"16 4","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13118264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Application of Artificial Intelligence in Anesthesiology: A Multicenter Retrospective Comparison Between Human Anesthetic Decisions and Algorithmic Recommendations in Non-Cardiac Surgery.","authors":"Gilberto Duarte-Medrano, Natalia Nuño-Lámbarri, Octavio Gonzalez-Chon, Rebeca Garazi Elguezabal Rodelo, Carmelo Calvagna, Daniele Paternò, Luigi La Via, Massimiliano Sorbello","doi":"10.3390/jpm16040222","DOIUrl":"https://doi.org/10.3390/jpm16040222","url":null,"abstract":"<p><p><b>Background</b>: Artificial intelligence (AI) is progressively entering perioperative medicine; however, its role in preoperative anesthetic decision-making remains insufficiently characterized. We evaluated the concordance between anesthesiologist-selected anesthetic techniques and algorithm-generated recommendations in a cohort of adult patients undergoing non-cardiac surgery. <b>Methods</b>: This retrospective observational study included adult patients (≥18 years) undergoing elective non-cardiac surgery between January 2024 and January 2025 at two international centers (Mexico and Italy). Clinical, demographic, and surgical variables were extracted from electronic medical records. For each case, a structured anonymized vignette was submitted to ChatGPT (version 5.0, medical configuration) to obtain an independent recommendation regarding anesthetic technique. Concordance between AI-generated and clinician-selected techniques was assessed using agreement analysis and stratified by country and surgical specialty. <b>Results</b>: A total of 1965 patients were analyzed. Overall concordance between ChatGPT recommendations and anesthesiologist-selected techniques was 84.6%. Agreement remained stable across centers (Mexico 84.3%; Italy 88.7%). Disagreement rates varied by surgical specialty, with the highest values observed in vascular and proctologic surgery (28.6%), followed by urology (21.1%) and thoracic surgery (18.8%). Orthopedic procedures-particularly shoulder arthroscopy-accounted for a relevant proportion of divergences, where AI frequently favored regional techniques over general anesthesia. No specialty demonstrated discordance exceeding 30%. <b>Conclusions</b>: AI-generated anesthetic recommendations demonstrated substantial concordance with expert clinical decision-making across heterogeneous surgical settings. These findings support the potential integration of AI within a hybrid decision-making framework, complementing-rather than replacing-anesthesiologist expertise in contemporary perioperative care.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"16 4","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13117377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the Gap Between Pharmacogenomic Discovery and Clinical Implementation: Insights from Selected Studies on Inter-Individual Variability in Drug Response.","authors":"Su-Jun Lee","doi":"10.3390/jpm16040221","DOIUrl":"https://doi.org/10.3390/jpm16040221","url":null,"abstract":"<p><p>Inter-individual variability in drug efficacy and toxicity remains a major challenge in modern healthcare, particularly as aging populations are increasingly exposed to polypharmacy and complex treatment regimens [...].</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"16 4","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13117048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of a Short-Stay Lumboperitoneal Shunt Pathway Based on Perioperative Optimization and Individualized Discharge Decision-Making: A Pilot Before-After Study.","authors":"Tatsuya Tanaka, Eiichi Suehiro, Anh Tran Hue, Ryosuke Doi, Shunsuke Hatakenaka, Junpei Kato, Tomihiro Wakamiya, Kimihiro Nakahara, Takashi Agari, Masahiro Indo, Takashi Sugawara, Hiroshi Itokawa, Kazuaki Shimoji, Keisuke Onoda, Akira Matsuno","doi":"10.3390/jpm16040223","DOIUrl":"https://doi.org/10.3390/jpm16040223","url":null,"abstract":"<p><p><b>Background</b>: Lumboperitoneal (LP) shunt surgery is an established treatment for idiopathic normal pressure hydrocephalus (iNPH). In Japan, patients undergoing LP shunt surgery are often hospitalized for several days to more than one week after surgery, even in uncomplicated cases, reflecting concerns regarding early complications, cerebrospinal fluid overdrainage, and discharge readiness in older adults. This study evaluated the feasibility and short-term safety of a perioperative optimization pathway for planned short-stay hospitalization after LP shunt surgery. <b>Methods</b>: This single-center retrospective before-and-after cohort study included 15 consecutive patients who underwent elective LP shunt surgery. Six patients were managed using a conventional hospitalization pathway, whereas nine patients were treated under a short-stay pathway targeting discharge after one postoperative night. Key perioperative modifications included a uniform higher initial programmable valve pressure (level 7), structured discharge education, scheduled postoperative analgesia, waterproof wound sealing permitting early showering, and early outpatient follow-up with head computed tomography for staged valve pressure adjustment. The primary outcome was 30-day safety, defined as readmission, reoperation, or major postoperative complications. <b>Results</b>: Baseline characteristics were generally comparable between groups, although the short-stay group was slightly older and had more frequent antithrombotic therapy. Mean hospital length of stay was shorter in the short-stay group than in the conventional group (3.7 ± 2.0 vs. 9.7 ± 0.8 days; median, 3 vs. 9.5 days). Orthostatic headache requiring valve adjustment occurred in three conventional cases but in none of the short-stay patients. No patients in the short-stay group required readmission or reoperation within 30 days. <b>Conclusions</b>: In this pilot before-and-after study, a short-stay LP shunt pathway incorporating perioperative optimization and individualized discharge decision-making was feasible and was not associated with an apparent increase in early adverse events. These findings should be interpreted as exploratory and may support further evaluation of short-stay management strategies for selected patients undergoing LP shunt surgery in Japan.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"16 4","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13117162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}